Announced Wed, 22 Jul · 13:44 IST
Regulation 57 compliance: no NCDs with payments due in Q1 FY27
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹3.05
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-2.0+0.0-1.6———————
Up moveDown movePending
AI summary
Transgene Biotek has submitted its quarterly compliance under SEBI LODR Regulation 57 for the quarter ended 30 June 2026. The company confirms that this regulation is not applicable to it because it has no non-convertible securities (NCDs) on which interest, dividend, or principal payments were due during the quarter. Signed by Dr K Koteswara Rao, Chairman and Managing Director.
Likely market impact
Routine procedural filing with no impact on shareholders or stock price, as the company has no NCD obligations.